Kiniksa’s Diversified Pipeline Augments Arcalyst Potential (NASDAQ:KNSA)

Heart burn or Pericarditis disease concept.Man

Pornpak Khunatorn/iStock via Getty Images

At a Glance

Kiniksa Pharmaceuticals (NASDAQ:KNSA) finds itself at a pivotal juncture, both clinically and financially. On the clinical front, Arcalyst is rapidly carving out a substantive role in the niche yet significant market of recurrent

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *